The evaluation of insulin secretion pattern on Japanese type 2 diabetes under the usage of DPP-4 inhibitor
Phase 4
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000002978
- Lead Sponsor
- Department of internal medicine, Kobe University Graduate School of medicine Division of Diabetes, Metabolism and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1.Patients with type 2 diabetes used either alpha-glucosidase inhibitors nor any insulin products 2.Patients who had allergy to DPP-4 inhibitor 3.Patients who had insulin allergy 4.type 1 diabetes 5.pancreatic diabetes 6.Patients who had anti-insulin antibodies 7.Serious liver or renal diseases 8.Other conditions precluding participation as judged by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in glycemic control (1 week after initiation of DPP-4 inhibitor therapy) (FPG, AUC PG during breakfast, 1,5-AG)
- Secondary Outcome Measures
Name Time Method 1.Change in insulin secretion (1 week after initiation of DPP-4 inhibitor therapy) (FIRI, Proinsulin/insulin ratio, HOMA-b, AUC IRI during breakfast) 2.Change in insulin sensitivity (1 week after initiation of DPP-4 inhibitor therapy) (HOMA-R) 3.Change in glucagon secretion (1 week after initiation of DPP-4 inhibitor therapy) ( FIRG, AUC IRG during breakfast